Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Larimar Therapeuticslarimartx.com · Low evidenceLarimar Therapeutics is a clinical-stage biotechnology company developing treatments for complex rare diseases. Its lead product candidate, nomlabofusp, is being evaluated in a Phase 2 clinical program for Friedreich's ataxia, a rare genetic disease.
Parse Score